126 related articles for article (PubMed ID: 33674271)
1. Metabolic Retroversion of Piperaquine (PQ) via Hepatic Cytochrome P450-Mediated
Xie Y; Zhang Y; Liu H; Xing J
Drug Metab Dispos; 2021 May; 49(5):379-388. PubMed ID: 33674271
[TBL] [Abstract][Full Text] [Related]
2. The Effect of Retroconversion Metabolism of
Zhou H; Zhang L; Ji J; Xie Y; Xing J
Curr Drug Metab; 2023; 24(2):131-138. PubMed ID: 36941813
[TBL] [Abstract][Full Text] [Related]
3. Interspecies comparison and role of human cytochrome P450 and flavin-containing monooxygenase in hepatic metabolism of L-775,606, a potent 5-HT(1D) receptor agonist.
Prueksaritanont T; Lu P; Gorham L; Sternfeld F; Vyas KP
Xenobiotica; 2000 Jan; 30(1):47-59. PubMed ID: 10659950
[TBL] [Abstract][Full Text] [Related]
4. Metabolism of Piperaquine to Its Antiplasmodial Metabolites and Their Pharmacokinetic Profiles in Healthy Volunteers.
Liu H; Zhou H; Cai T; Yang A; Zang M; Xing J
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29784841
[TBL] [Abstract][Full Text] [Related]
5. Metabolism is not a Major Contributor to the Toxicity of Piperaquine, a Long-acting Antimalarial Agent in Artemisinin-based Combination Therapy.
Zhang L; Liu Z; Zhang Y; Xie Y; Xing J
Curr Drug Metab; 2021; 22(10):824-834. PubMed ID: 34602032
[TBL] [Abstract][Full Text] [Related]
6. In vitro metabolism of piperaquine is primarily mediated by CYP3A4.
Lee TM; Huang L; Johnson MK; Lizak P; Kroetz D; Aweeka F; Parikh S
Xenobiotica; 2012 Nov; 42(11):1088-95. PubMed ID: 22671777
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CYP3A by Antimalarial Piperaquine and Its Metabolites in Human Liver Microsomes With IVIV Extrapolation.
Aziz MY; Hoffmann KJ; Ashton M
J Pharm Sci; 2018 May; 107(5):1461-1467. PubMed ID: 29352982
[TBL] [Abstract][Full Text] [Related]
8. Cyclic conversion of the novel Src kinase inhibitor [7-(2,6-dichloro-phenyl)-5-methyl-benzo[1,2,4]triazin-3-yl]-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-amine (TG100435) and Its N-oxide metabolite by flavin-containing monoxygenases and cytochrome P450 reductase.
Kousba A; Soll R; Yee S; Martin M
Drug Metab Dispos; 2007 Dec; 35(12):2242-51. PubMed ID: 17881660
[TBL] [Abstract][Full Text] [Related]
9. The impact of individual human cytochrome P450 enzymes on oxidative metabolism of anticancer drug lenvatinib.
Vavrová K; Indra R; Pompach P; Heger Z; Hodek P
Biomed Pharmacother; 2022 Jan; 145():112391. PubMed ID: 34847475
[TBL] [Abstract][Full Text] [Related]
10. Identification of CYP3A4 as the primary cytochrome P450 responsible for the metabolism of tandospirone by human liver microsomes.
Natsui K; Mizuno Y; Tani N; Yabuki M; Komuro S
Eur J Drug Metab Pharmacokinet; 2007; 32(3):131-7. PubMed ID: 18062405
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes.
Xing J; Kirby BJ; Whittington D; Wan Y; Goodlett DR
Drug Metab Dispos; 2012 Sep; 40(9):1757-64. PubMed ID: 22679214
[TBL] [Abstract][Full Text] [Related]
12. Identification of the cytochrome P450 enzymes involved in the N-demethylation of sildenafil.
Hyland R; Roe EG; Jones BC; Smith DA
Br J Clin Pharmacol; 2001 Mar; 51(3):239-48. PubMed ID: 11298070
[TBL] [Abstract][Full Text] [Related]
13. Identification of cytochrome P450 enzymes involved in the metabolism of zotepine, an antipsychotic drug, in human liver microsomes.
Shiraga T; Kaneko H; Iwasaki K; Tozuka Z; Suzuki A; Hata T
Xenobiotica; 1999 Mar; 29(3):217-29. PubMed ID: 10219963
[TBL] [Abstract][Full Text] [Related]
14. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
15. Metabolism and pharmacokinetics characterization of metarrestin in multiple species.
Padilha EC; Shah P; Wang AQ; Singleton MD; Hughes EA; Li D; Rice KA; Konrath KM; Patnaik S; Marugan J; Rudloff U; Xu X
Cancer Chemother Pharmacol; 2020 Apr; 85(4):805-816. PubMed ID: 32185484
[TBL] [Abstract][Full Text] [Related]
16. No Effect of PXR (8055C>T) Polymorphism on the Pharmacokinetic Profiles of Piperaquine in Healthy Chinese Subjects.
Liu H; Xie Y; Cai T; Xing J
Curr Drug Metab; 2022; 23(2):164-170. PubMed ID: 35168517
[TBL] [Abstract][Full Text] [Related]
17. Metabolite identification of the antimalarial piperaquine in vivo using liquid chromatography-high-resolution mass spectrometry in combination with multiple data-mining tools in tandem.
Yang A; Zang M; Liu H; Fan P; Xing J
Biomed Chromatogr; 2016 Aug; 30(8):1324-30. PubMed ID: 26821381
[TBL] [Abstract][Full Text] [Related]
18. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.
Ghosal A; Ramanathan R; Yuan Y; Hapangama N; Chowdhury SK; Kishnani NS; Alton KB
Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338
[TBL] [Abstract][Full Text] [Related]
19. Role of cytochrome P450 3A in the metabolism of mefloquine in human and animal hepatocytes.
Fontaine F; de Sousa G; Burcham PC; Duchêne P; Rahmani R
Life Sci; 2000 Apr; 66(22):2193-212. PubMed ID: 10834303
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Characterization of Ertugliflozin Metabolism by UDP-Glucuronosyltransferase and Cytochrome P450 Enzymes.
Lapham K; Callegari E; Cianfrogna J; Lin J; Niosi M; Orozco CC; Sharma R; Goosen TC
Drug Metab Dispos; 2020 Dec; 48(12):1350-1363. PubMed ID: 33020067
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
